The strong Q2 beat and raised profitability trajectory (net income +142% YoY) support a bullish read-through for near-term price action, despite the slight guidance trim attributed to temporary DME destocking. Watch for the Q3 2026 earnings call for updates on AffloVest ordering normalization and any further guidance adjustments, which could clarify the recovery trajectory for the airway clearance segment.
Price Chart
Executive Summary
Tactile Systems Technology reported Q2 2026 results with total revenue of $85.7 million (up 9% YoY), net income of $7.8 million ($0.34 per diluted share) versus $3.2 million in Q2 2025, and adjusted EBITDA of $11.4 million. Revenue slightly beat the $85.5M consensus estimate, while EPS of $0.34 far exceeded the $0.14 consensus forecast. However, the company narrowed its full-year 2026 revenue guidance to $360M–$366M (from $360M–$368M) due to temporary inventory destocking at DME providers, partially offsetting the strong quarter.
Key Financial Metrics
Key Facts
- Total revenue of $85.7 million for Q2 2026, up 9% YoY from $78.9 million
- Net income of $7.8 million ($0.34 diluted EPS) vs $3.2 million ($0.14) in Q2 2025
- Gross margin expanded to 76% from 75% in Q2 2025
- Adjusted EBITDA of $11.4 million, up 49% from $7.7 million
- Lymphedema product revenue grew 12% to $73.6 million; airway clearance revenue fell 7% to $12.1 million due to DME inventory dynamics
- FY 2026 revenue guidance narrowed to $360M–$366M (prior: $360M–$368M); reaffirmed adjusted EBITDA guidance of $49M–$51M
- Repurchased $5.3 million of stock in Q2 2026; $18.7 million remaining under the $25M buyback program
- Cash balance of $69.9 million with zero debt as of June 30, 2026
Financial Impact
Q2 revenue beat consensus by +0.2% ($85.7M vs $85.5M); EPS of $0.34 significantly exceeded consensus of $0.14 (143% beat). Full-year guidance midpoint lowered by $1M to $363M, representing ~10% YoY growth.
Risk Factors
- Airway clearance revenue declined 7% YoY due to DME inventory destocking; continued weakness could pressure future revenue growth
- Narrowed FY 2026 revenue guidance range signals less confidence in full-year top-line acceleration
- Competitive dynamics in the airway clearance market could affect AffloVest adoption
- Litigation and acquisition integration costs ($156K in Q2) weigh on reported net income
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-093346 |
| Document: tcmd-20260810x8k.htm | 0001104659-26-093346 |
| Document: 0001104659-26-093346-index-headers.html | 0001104659-26-093346 |
| Document: 0001104659-26-093346-index.html | 0001104659-26-093346 |
| Document: 0001104659-26-093346.txt | 0001104659-26-093346 |
| 8-K Data (Synthetic) | 0001104659-26-093346 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 7w ago | Press Release | $24.15 $22.02 | ▼ −8.82% | ▼ −7.76% | $22.35 (−7.43%) |
Aug 10, 2026 7w ago | 8-K | $24.15 $22.02 | ▼ −8.82% | ▼ −7.76% | $22.35 (−7.43%) |
Jul 13, 2026 11w ago | 8-K | $29.04 $29.14 | ▲ +0.34% | ▼ −2.84% | $22.35 (−23.02%) |
Jun 11, 2026 16w ago | Institutional Cluster | $26.35 $30.68 | ▲ +16.43% | ▲ +14.54% | $22.35 (−15.16%) |
Apr 20, 2026 23w ago | Press Release | $24.80 $23.65 | ▼ −4.64% | ▼ −9.55% | $22.35 (−9.86%) |
Mar 25, 2026 27w ago | DEFA14A | $26.96 $24.45 | ▼ −9.31% | ▼ −17.17% | $22.35 (−17.08%) |
Feb 23, 2026 31w ago | Insider Cluster | $28.66 $26.51 | ▼ −7.50% | ▼ −3.56% | $22.35 (−22.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access